NCT00095563 · OUTCOME

Most Frequent Adverse Events of Grade 1-2 by CTCAE Grading

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers · Source last updated 2017-04-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: Up to 5 years

What was measured

Number of participants that experienced the most frequent adverse events of grade 1-2 by CTCAE grading.

Groups in this outcome

Treatment (Lapatinib Ditosylate)

Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. lapatinib ditosylate: Given orally laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Lapatinib Ditosylate)	39

Reported measurements

Diarrhea

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Lapatinib Ditosylate)	26	Not reported	Not reported	Not reported	Not reported

Fatigue

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Lapatinib Ditosylate)	28	Not reported	Not reported	Not reported	Not reported

Rash

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Lapatinib Ditosylate)	19	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
26
title
Diarrhea
categories
measurements
group Id
OG000
value
28
title
Fatigue
categories
measurements
group Id
OG000
value
19
title
Rash

denoms

counts
group Id
OG000
value
39
units
Participants

description

Number of participants that experienced the most frequent adverse events of grade 1-2 by CTCAE grading.

groups

description
Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. lapatinib ditosylate: Given orally laboratory biomarker analysis: Correlative studies
id
OG000
title
Treatment (Lapatinib Ditosylate)

param Type

NUMBER

reporting Status

POSTED

time Frame

Up to 5 years

title

Most Frequent Adverse Events of Grade 1-2 by CTCAE Grading

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice